A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
Clinical trial NCT05689203 · UNKNOWN
Trial details
- NCT number
- NCT05689203
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-30
- Primary completion
- 2023-02-01
- Enrollment
- 360
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.